Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17337609 | 1.00 | ROCK2 (0.41) | ROCK2ALDH1A1EGLN3TBXAS1MEN1 | |
| SCHEMBL17347848 | 0.90 | KDM4E (0.43) | ROCK2ALDH1A1TBXAS1MEN1KMT2A | |
| SCHEMBL23129890 | 0.89 | ROCK2 (0.39) | ROCK2ALDH1A1TBXAS1MEN1KMT2A | |
| SCHEMBL17337153 | 0.88 | TBXAS1 (0.46) | ROCK2ALDH1A1TBXAS1MEN1KMT2A | |
| SCHEMBL17337151 | 0.88 | TBXAS1 (0.46) | ROCK2ALDH1A1TBXAS1MEN1KMT2A | |
| SCHEMBL23837398 | 0.88 | ROCK2 (0.38) | ROCK2ALDH1A1EGLN3TBXAS1MEN1 | |
| SCHEMBL17337337 | 0.85 | TBXAS1 (0.39) | ROCK2ALDH1A1TBXAS1MEN1KMT2A | |
| SCHEMBL23837599 | 0.85 | TBXAS1 (0.37) | ROCK2ALDH1A1TBXAS1MEN1KMT2A | |
| SCHEMBL17337339 | 0.85 | TBXAS1 (0.39) | ROCK2ALDH1A1TBXAS1MEN1KMT2A | |
| SCHEMBL17337059 | 0.85 | KMT2A (0.41) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3882252-B1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2025-11-19 | — | — | EP | disclosed |
| EP-3882252-A1 | BETA-LACTAMASE INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2021-09-22 | — | — | EP | disclosed |
| US-11008346-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3154989-B1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20200361962-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-11-19 | — | — | US | disclosed |
| US-9926336-B2 | Beta-lactamase inhibitors | VENATORX PHARMACEUTICALS (US) | 2018-03-27 | — | — | US | disclosed |
| US-20170342092-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-11-30 | — | — | US | disclosed |
| US-9783555-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170226135-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-08-10 | — | — | US | disclosed |
| US-9637504-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2017-05-02 | — | — | US | disclosed |
| EP-3154989-A1 | BETA-LACTAMASE INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2017-04-19 | — | — | EP | disclosed |
| US-20160264598-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-15 | — | — | US | disclosed |
| WO-2015191907-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008346-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | ROCK2 2893/4885ALDH1A1 305/4885EGLN3 1778/4885 |
| US-20170342092-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | ROCK2 2893/4885ALDH1A1 305/4885EGLN3 1778/4885 |
| US-20200361962-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | ROCK2 2893/4885ALDH1A1 305/4885EGLN3 1778/4885 |
| US-20170226135-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | ROCK2 2893/4885ALDH1A1 305/4885EGLN3 1778/4885 |
| US-20160264598-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | ROCK2 2893/4885ALDH1A1 305/4885EGLN3 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.